Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Bacilli class" patented technology

Bacilli refers to a taxonomic class of bacteria. It includes two orders, Bacillales and Lactobacillales, which contain several well-known pathogens such as Bacillus anthracis (the cause of anthrax).

Carbonate-containing granular material production method

PCT designated stageWO2026110421A1FermentationBacteroides speciesSporobacter
Provided is a carbonate-containing granular material production method with which it is possible to produce a carbonate-containing granular material at a cost lower than when using conventional methods. The present invention has a carbonation step for bringing, into contact with a carbonation-target granular material at a maximum temperature of higher than 0°C to lower than 100°C, either water, a carbonation accelerator, and at least one among a carbon dioxide-containing substance, a carbonate ion-containing water, and a hydrogen carbonate ion-containing water, or a carbonation accelerator and at least one among a carbon dioxide-containing water, a carbonate ion-containing water, and a hydrogen carbonate ion-containing water. The total amount of water brought into contact in the carbonation step is 1 mass% or more of the carbonation-target granular material. The carbonation accelerator contains bacteria. The bacteria are at least one selected from the genus Bacillus, the family Bacillaceae, the class Bacilli, the family Clostridiaceae, the family Micrococcaceae, the family Microbacteriaceae, or the family Comamonadaceae.
Owner:JFE STEEL CORP

Lactobacillus brevis strain D15 for salt-reduced Pixian thick broad-bean sauce and application of lactobacillus brevis strain D15

The invention discloses a lactobacillus brevis strain D15 for salt-reduced Pixian thick broad-bean sauce and application of the lactobacillus brevis strain D15. The preservation registration number of the strain D15 is CGMCC (China General Microbiological Culture Collection Center) No: 27698. The botanical classification of the strain D15 is short-growth-promoting lactobacillus in the bacterial field, the phylum of Thyrium, the Bacillus, the Lactobacillus, the Lactobacillus family and the Lactobacillus genus, and the Latin literature name of the strain D15 is Levibacillus brevis D15. The application of the strain D15 is as follows: firstly, the strain D15 is applied to preparation of salt-reduced Pixian thick broad-bean sauce; 2, application in preparation of salt-reduced chilli sauce; and 3, application in preparation of the salt-reduced broad bean sauce. After inoculation optimization is carried out on chili embryos or broad bean embryos by using the strain D15 disclosed by the invention, a salt-reduced fermentation system which takes chili and broad beans as raw materials and is under low salinity can be kept stable, the pH value is 4.2-4.5, and rancidity of the prepared fermented food is avoided; the enzyme activity can be obviously promoted, the fermentation time is shortened, the preparation cost is reduced, the flavor quality of the Pixian thick broad-bean sauce, the chili sauce and the broad bean sauce is obviously improved, and the industrial application value of the Pixian thick broad-bean sauce is obviously improved.
Owner:INST OF AGRO PROD PROCESSING SCI & TECH SICHUAN ACAD OF AGRI SCI

Bacillus orientalis and application thereof

The invention discloses bacillus toonensis, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation date is February 2, 2024, and the preservation number is CGMCC No.29852. The bacillus toonensis belongs to the eubacterium field, the posterior mycophylum, the bacilli, the bacillus family and the bacillus genus. The bacterial suspension of the bacillus orientalis can be used for degrading cellulose, starch and straw.
Owner:ZUNYI CITY BRANCH OF GUIZHOU TOBACCO COMPANY +2

Novel N-glycosidase with high expression and high activity, production method and application thereof

The present invention relates to a novel fusion polypeptide comprising a polypeptide having N-glycosidase activity fused to an antioxidant moiety wherein the polypeptide having N-glycosidase activity is a polypeptide from a bacterium belonging to the phylum of Acidobacteria, preferably belonging to the class of Acidobacteria. The invention also relates to nucleic acid molecules, vectors and host cells encoding the fusion polypeptides, as well as compositions and kits thereof. The invention also provides methods for purification and / or for production of the fusion polypeptides, as well as in vitro uses of the fusion polypeptides or nucleic acid molecules, vectors or host cells encoding the fusion polypeptides or compositions thereof.
Owner:PARIS SCI & LETTRES +2

Intestinal microbial markers for mesenchymal stromal cell treatment of crohn's disease, products and uses thereof

PendingCN122629194ALactobacillaceaeBacteroidia
The application discloses an intestinal microorganism marker for mesenchymal stromal cells treating Crohn's disease, a product and application thereof, and provides the intestinal microorganism marker, which comprises one or more of the following: order of erysipelotrichales, genus of faecalibacterium, family of erysipelotrichaceae, class of bacilli, order of lactobacillales, family of lactobacillaceae, genus of lactobacillus, phylum of firmicutes, family of muribaculaceae, order of bacteroidales, class of bacteroidia, phylum of bacteroidetes, class of clostridia, order of lachnospirales, family of lachnospiraceae, class of clostridia UCG-014 and order of oscillatolales. The content or abundance of the above marker can be detected to predict the curative effect of mesenchymal stromal cells treating Crohn's disease. The application further provides a method for constructing a curative effect prediction model based on the above marker, and obtains the curative effect prediction model. The application can realize the early prediction of the curative effect of mesenchymal stromal cells treating Crohn's disease, and has a good clinical application prospect.
Owner:JINAN MICROECOLOGY & BIOMEDICINE PROVINCIAL LAB

Use of enterococcus in combination with berberine in the treatment of phenylketonuria

The application relates to the technical field of medicines, and provides application of a composition of enterococcus and berberine or a salt thereof in preparation of medicines for preventing and / or treating phenylketonuria. Specifically, the enterococcus can significantly metabolize phenylalanine in an in-vitro culture medium system; the enterococcus belongs to the firmicutes, the bacilli class, the lactobacillus order and the enterococcus family. Meanwhile, the enterococcus and the berberine can be combined to significantly treat the phenylketonuria; the plasma phenylalanine of the phenylketonuria milk mouse can be reduced by 34.2% after 4 weeks of treatment, which indicates that the enterococcus and the berberine have an outstanding treatment effect in preventing and / or treating the phenylketonuria.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI